Extracellular vesicle based therapeutic targeting of b-catenin to modulate anti-cancer immune responses in Hepatocellular Cancer

Combination therapy with anti PD-1 and β -catenin siRNA delivered using biological nanoparticles provide an effective strategy for the treatment of Hepatocellular carcinoma. A synthetic transgenic mouse of experimental HCC induced by MET/ β-catenin expression, and extracellular vesicles as a therapeutic delivery agent were used to evaluate the efficacy of directly targeting β-catenin on response to anti-PD-1. This series includes data only for anti-PD-1.